Pharmacological and clinical evaluation of Dorzagliatin in the treatment of type 2 diabetes
10.12092/j.issn.1009-2501.2023.10.012
- Author:
Xiaoyu DU
1
;
Yumeng LI
1
;
Huizhen WU
2
;
Bo QIU
2
Author Information
1. Graduate School of Hebei Medical University
2. Department ofPharmacy, Hebei General Hospital
- Publication Type:Journal Article
- Keywords:
Dorzagliatin;
glucokinase;
HMS5552;
type 2 diabetes
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2023;28(10):1177-1183
- CountryChina
- Language:Chinese
-
Abstract:
Dorzagliatin is a new dual action allosteric systemic glucokinase agonist (GKA), which can simultaneously activate the glucokinase (GK) in the pancreas and liver, promote insulin secretion and liver glycogen conversion in patients with type 2 diabetes, and improve pancreatic islets β - Cell function and insulin resistance simultaneously stimulate intestinal GK to regulate the secretion of Glucagon-like peptide-1 to play multiple hypoglycemic effects. As the first marketed GKA drug, it provides a new therapeutic approach for patients with type 2 diabetes. This article reviews the mechanism of action, pharmacokinetics, Drug interaction, clinical research and safety of Dorzagliatin.
